The role of stem cells in the treatment of primary pulmonary hypertension

Determining the effect of stem cell injection on clinical symptoms and echocardiographic findings of children with primary pulmonary artery hypertension

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210317050737N2

Enrollment

Registered

2023-02-06

Start date

2022-11-22

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary pulmonary hypertension. Primary pulmonary hypertension

Interventions

Intervention 1: Intervention group: Stem cell injection of one and a half milliliter per kilogram of the patient's weight from processed stem cells with a concentration of one million stem cells in 20

Eligibility

Sex/Gender

All

Age

3 Years to 18 Years

Inclusion criteria

Inclusion criteria: All patients aged 3-8 years diagnosed with primary pulmonary hypertension

Exclusion criteria

Exclusion criteria: Accompanying congenital heart disease Secondary causes of pulmonary hypertension

Design outcomes

Primary

Measure	Time frame
Pulmonary arterial pressure. Timepoint: Before injection and after injection at intervals of 24 and 48 hours, one and 6 months later. Method of measurement: Transthoracic echocardiography.;6 minute walk test. Timepoint: Before injection and after injection at intervals of 24 and 48 hours, one and 6 months later. Method of measurement: Observing and measuring the distance traveled.;Arterial oxygen saturation percentage. Timepoint: Before injection and after injection at intervals of 24 and 48 hours, one and 6 months later. Method of measurement: Pulse oximetry.	—

Measure

Time frame

Pulmonary arterial pressure. Timepoint: Before injection and after injection at intervals of 24 and 48 hours, one and 6 months later. Method of measurement: Transthoracic echocardiography.;6 minute walk test. Timepoint: Before injection and after injection at intervals of 24 and 48 hours, one and 6 months later. Method of measurement: Observing and measuring the distance traveled.;Arterial oxygen saturation percentage. Timepoint: Before injection and after injection at intervals of 24 and 48 hours, one and 6 months later. Method of measurement: Pulse oximetry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Ahmadipour

Kerman University of Medical Sciences

maryam.ahmadipour5@gmail.com+98 34 2235 0118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026